<Suppliers Price>

AAL 993

Names

[ CAS No. ]:
269390-77-4

[ Name ]:
AAL 993

[Synonym ]:
2-[(pyridin-4-ylmethyl)amino]-N-[3-(trifluoromethyl)phenyl]benzamide
2-((4-pyridyl)methyl)amino-N-(3-(trifluoromethyl)phenyl)benzamide
2-[(4-Pyridinylmethyl)amino]-N-[3-(trifluoromethyl)phenyl]benzamide
Benzamide, 2-[(4-pyridinylmethyl)amino]-N-[3-(trifluoromethyl)phenyl]-
AAL993

Biological Activity

[Description]:

IC50s of 130 nM, 23 nM, and 18 nM for VEGFR1, VEGFR2, and VEGFR3, respectively. AAL993 shows less potently inhibits other tyrosine kinases. AAL993 possesses potent antiangiogenic and antitumor properties[1].

[Related Catalog]:

Research Areas >> Cancer
Research Areas >> Cardiovascular Disease
Signaling Pathways >> Protein Tyrosine Kinase/RTK >> VEGFR

[Target]

VEGFR1:130 nM (IC50)

VEGFR2:23 nM (IC50)

VEGFR3:18 nM (IC50)


[In Vitro]

AAL993 suppresses HIF-1α expression through ERK inhibition without affecting Akt phosphorylation[2].

[In Vivo]

AAL993 (compound 5) potently inhibits VEGF-induced angiogenesis in an implant model, with an ED50 value of 7 mg/kg[1]. In B16 melanoma xenograft model, AAL993 (24-100 mg/kg; p.o.; daily; for 14days) inhibits both the growth of the primary tumor as well as the formation of spontaneous peripheral metastases[1].

[References]

[1]. Paul W Manley , et al. Anthranilic acid amides: a novel class of antiangiogenic VEGF receptor kinase inhibitors. J Med Chem. 2002 Dec 19;45(26):5687-93.

[2]. Hyun Seung Ban, et al. Suppression of hypoxia-induced HIF-1alpha accumulation by VEGFR inhibitors: Different profiles of AAL993 versus SU5416 and KRN633. Cancer Lett. 2010 Oct 1;296(1):17-26.

Chemical & Physical Properties

[ Density]:
1.3±0.1 g/cm3

[ Boiling Point ]:
441.3±45.0 °C at 760 mmHg

[ Molecular Formula ]:
C20H16F3N3O

[ Molecular Weight ]:
371.356

[ Flash Point ]:
220.7±28.7 °C

[ Exact Mass ]:
371.124542

[ PSA ]:
57.51000

[ LogP ]:
4.51

[ Vapour Pressure ]:
0.0±1.1 mmHg at 25°C

[ Index of Refraction ]:
1.631

Related Compounds